Ovintiv's Q2 2024 earnings per share (EPS) of $1.23 missed the analyst consensus estimate of $1.31 by 6.11%. Additionally, the company's sales of $2.288 billion missed the $2.441 billion estimate by 6.25% and were down 9.10% from the same period last year. These misses on both earnings and sales, coupled with a significant year-over-year decline in sales, are likely to exert downward pressure on the stock price in the short term.